No More Big Fish In A Small Pond: Yuhan Opts For Globalization For Long-Term Growth
After clinching massive licensing-out agreements with multinationals last year, Yuhan is setting out a long-term global road map with a determination that it won’t just remain top in the South Korean market. The head of the firm's newly established global strategy department talks to Scrip how and why it aims to achieve globalization in the next decade and beyond.
You may also be interested in...
The head of the US arm of a major Korean government development institute talks to Scrip about why biotechs and pharma firms are flocking to Boston, how the organization is providing support and what the main challenges are.
Although South Korean pharma firms are largely sailing toward the common goal of globalization, they have different strategies to reach their goals. Scrip takes a look at the variety of paths being pursued.
The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.